ALX ONCOLOGY HOLDINGS INC Operating Lease, Expense
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Operating Lease, Expense of $600.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2021-03-18
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for the quarter ending 2020-12-31 was $100.00K, a 50.00% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for the quarter ending 2020-09-30 was $100.00K, a 50.00% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for the quarter ending 2020-06-30 was $200.00K, a 0.00% change year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for the quarter ending 2020-03-31 was $200.00K.
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for fiscal 2020 was $600.00K, a 25.00% decline from fiscal 2019.
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for fiscal 2019 was $800.00K, a 20.00% decline from fiscal 2018.
- ALX ONCOLOGY HOLDINGS INC operating lease, expense for fiscal 2018 was $1.00M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $200.00K derived: sum of 2 quarters · filed 2021-03-18 | $400.00K derived: sum of 3 quarters · filed 2021-03-18 | $600.00K 10-K · filed 2021-03-18 |
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-12 | $300.00K derived: sum of 2 quarters · filed 2020-11-12 | $500.00K 10-Q · filed 2020-11-12 | $700.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2020-06-30 | $200.00K 10-Q · filed 2020-08-27 | $400.00K 10-Q · filed 2020-08-27 | $600.00K derived: sum of 3 quarters · filed 2021-03-18 | $800.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2020-03-31 | $200.00K derived: 10-K 12 month − 3 quarters · filed 2021-03-18 | $400.00K derived: sum of 2 quarters · filed 2021-03-18 | $600.00K derived: sum of 3 quarters · filed 2021-03-18 | $800.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $400.00K derived: sum of 2 quarters · filed 2021-03-18 | $600.00K derived: sum of 3 quarters · filed 2021-03-18 | $800.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-12 | $400.00K derived: sum of 2 quarters · filed 2020-11-12 | $600.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-27 | $400.00K 10-Q · filed 2020-08-27 | ||
| 2018-12-31 | $1.00M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |